Cargando…

Clinicopathologic and molecular analysis of a BCOR–CCNB3 undifferentiated sarcoma of the kidney reveals significant epigenetic alterations

Undifferentiated soft tissue sarcomas (UDSTSs) are a group of mesenchymal tumors that remain a diagnostic challenge because of their morphologic heterogeneity and unclear histologic origin (Peters et al., Mod Pathol 28: 575 [2015]). In this case report, we present the first multiomics molecular sign...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagoel, Tamara J., Cortes Gomez, Eduardo, Gupta, Ajay, Twist, Clare J., Kozielski, Rafal, Martin, Jeffrey C., Gao, Lingui, Kuechle, Joseph, Singh, Prashant K., Lynch, Miranda, Wei, Lei, Liu, Song, Wang, Jianmin, Ohm, Joyce E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744494/
https://www.ncbi.nlm.nih.gov/pubmed/34819304
http://dx.doi.org/10.1101/mcs.a005942
Descripción
Sumario:Undifferentiated soft tissue sarcomas (UDSTSs) are a group of mesenchymal tumors that remain a diagnostic challenge because of their morphologic heterogeneity and unclear histologic origin (Peters et al., Mod Pathol 28: 575 [2015]). In this case report, we present the first multiomics molecular signature for a BCOR–CCNB3 sarcoma (BCS) that includes mutation analysis, gene expression, DNA methylation, and micro RNA (miRNA) expression. We identify a paucity of additional mutations in this tumor and detail that there is significant dysregulation of gene expression of epigenetic remodeling agents including key members of the PRC, Sin3A/3b, NuRD, and NcoR/SMRT complexes and the DNA methyltransferases DNMT1, DNMT3a, and DNMT3b. This is accompanied by significant DNA methylation changes and dysregulation of multiple miRNAs with known links to tumorigenesis. This study significantly increases our understanding of the BCOR effects on fusion-positive undifferentiated sarcomas at both the genomic and epigenomic level and suggests that as better-tailored and more refined treatment algorithms continue to evolve, epigenetic modifying agents should be further evaluated for their efficacy against these tumors.